shutterstock_1246881214_piotr_swat
Piotr Swat / Shutterstock.com
1 February 2022AmericasMuireann Bolger

Celgene, Dr Reddy's abandon cancer drug patent dispute

Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst (pomalidomide).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
11 February 2021   Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment.
Americas
1 October 2020   A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.
Americas
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.

More on this story

Big Pharma
11 February 2021   Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment.
Americas
1 October 2020   A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.
Americas
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.

More on this story

Big Pharma
11 February 2021   Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment.
Americas
1 October 2020   A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.
Americas
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.